Bioextrax AB (BIOEX) AI Stock Analysis

• Market Cap: kr121.57M
• Dividend Yield: N/A
• Average Volume (3M): 120.44K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.03
• Revenue Growth: -74.96%
• EPS Growth: 32.88%
• Country: SE
• Employees: 14
• Sector: Industrials
• Sector Strength: 83
• Industry: Waste Management
• EPS (TTM): -0.10
• Shares Outstanding: 39,729,134
• 10 Day Avg. Volume: 94,444
• 30 Day Avg. Volume: 120,442
• PEG Ratio: -0.05
• Price to Book (P/B): 1.83
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.38
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 32 Underperform
• Price Target: ―

Bioextrax AB struggles with persistent financial losses, negative cash flows, and operational inefficiencies, reflected in a low financial performance score. The technical analysis indicates a lack of momentum, with the stock trading below major moving averages. Valuation metrics, particularly the negative P/E ratio, highlight concerns over financial stability and market perception. These factors collectively result in a low overall stock score.

Bioextrax AB Business Overview & Revenue Model

Company Description

Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. It harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids from bacteria. The company was incorporated in 2014 and is based in Lund, Sweden.

How the Company Makes Money

Bioextrax AB makes money primarily through licensing its proprietary technologies to companies in various industries seeking sustainable solutions for waste conversion and bioplastic production. The company's revenue streams include licensing fees, royalties from industrial partners utilizing their technology, and collaborative development agreements. Strategic partnerships with companies in sectors such as packaging, agriculture, and waste management also contribute significantly to its earnings by driving the adoption of Bioextrax's environmentally friendly processes.

Bioextrax AB Financial Statement Overview

Summary

Bioextrax AB faces significant financial challenges with persistent losses and negative cash flows, undermining profitability and growth prospects. Despite a debt-free balance sheet, the company struggles with operational efficiency and cash generation, which may hinder future growth unless addressed.

Income Statement

Bioextrax AB shows a consistently negative gross profit margin, indicating that the cost of goods sold exceeds revenue. The net profit margin is also consistently negative, reflecting significant net losses. Revenue growth is unstable, with recent declines, and both EBIT and EBITDA margins are negative due to high operating expenses relative to revenue.

Balance Sheet

The company maintains a debt-free balance sheet, which is a positive indicator of financial stability. However, the return on equity is negative due to net losses, which affects shareholder value. The equity ratio is strong, suggesting a solid capital structure with equity financing outweighing liabilities.

Cash Flow

Operating cash flows are consistently negative, indicating challenges in generating cash from core operations. Free cash flow is also negative, reflecting the ongoing need for external financing. The ratios of operating and free cash flow to net income reflect the company's difficulty in translating accounting profits into cash flow.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
515.00K	2.06M	395.00K	275.76K	21.78K
	Gross Profit
-915.00K	718.00K	-18.64M	-11.29M	-5.75M
	EBIT
-17.54M	-21.60M	-20.62M	-11.29M	-5.75M
	EBITDA
-16.18M	-20.65M	-18.19M	-10.18M	-5.40M
	Net Income Common Stockholders
-17.34M	-21.51M	-18.67M	-10.53M	-5.57M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
17.27M	13.40M	27.53M	8.98M	2.05M
	Total Assets
29.00M	22.52M	37.92M	12.64M	3.03M
	Total Debt
0.00	0.00	0.00	0.00	0.00
	Net Debt
-17.27M	-13.40M	-27.53M	-8.98M	-2.05M
	Total Liabilities
2.94M	1.98M	6.15M	5.14M	1.38M
	Stockholders Equity
26.06M	20.54M	31.77M	7.50M	1.65M
Cash Flow		Free Cash Flow
-18.99M	-24.41M	-24.38M	-9.45M	-4.32M
	Operating Cash Flow
-18.78M	-23.31M	-17.60M	-8.48M	-4.17M
	Investing Cash Flow
-215.00K	-1.10M	-6.78M	-975.13K	-151.00K
	Financing Cash Flow
22.86M	10.28M	42.94M	16.38M	5.79M

Bioextrax AB Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 3.08
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BIOEX, the sentiment is Neutral. The current price of 3.08 is below the 20-day moving average (MA) of 3.12, above the 50-day MA of 2.78, and below the 200-day MA of 3.09, indicating a neutral trend. The MACD of 0.10 indicates Positive momentum. The RSI at 53.00 is Neutral, neither overbought nor oversold. The STOCH value of 34.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:BIOEX.

Bioextrax AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	66 Neutral	$4.46B	12.15	5.40%	4.71%	4.16%	-11.97%
BIOEX	32 Underperform	kr121.57M	―	-92.43%	―	-74.96%	32.88%
1HR		€80.52M	11.19	-0.28%	―	―	―
8Y1		€12.29M	―	-35.25%	―	―	―
BO6		€7.03M	―	-103.44%	―	―	―
CRB		€6.10M	77.08		―	―	―
6WZ0		€5.65M	―	-36.51%	―	―	―